Freenome Stock
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Funding History
| June 2016 | $5.5M |
|---|---|
| March 2017 | $65.0M |
| August 2017 | $7.0M |
Management
Co-Founder, COO
Riley Ennis
Data Scientist
Kate Niehaus
Co-Founder, CTO
Michael Otte
Chief Bioinformatician
Adam Drake
CEO, Co-Founder
Gabriel Otte
Press
These South Bay and Peninsula cities are raking in venture capital
TechCrunch - Jul, 8 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Freenome or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
